<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025571</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068974</org_study_id>
    <secondary_id>RPCI-RP-0005</secondary_id>
    <nct_id>NCT00025571</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Study of Photodynamic Therapy (PDT) Using 2-(1-hexyloxyethyl)-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Early Stage Lung Cancer - A Dose Ranging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to&#xD;
      light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells&#xD;
      and, when exposed to light, become active and kill the tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of photodynamic therapy with HPPH in&#xD;
      treating patients who have non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the systemic and normal tissue toxicity of photodynamic therapy with HPPH in&#xD;
           patients with early stage or centrally obstructing non-small cell lung cancer.&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of HPPH.&#xD;
&#xD;
      Patients receive HPPH IV over 1 hour on day 1. Patients undergo laser light therapy via&#xD;
      bronchoscopy on day 3.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of HPPH until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed for at least 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 15-17 patients will be accrued for this study within 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPPH</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed microinvasive or centrally obstructing non-small cell lung&#xD;
             cancer&#xD;
&#xD;
               -  Squamous cell carcinoma&#xD;
&#xD;
               -  Adenocarcinoma&#xD;
&#xD;
               -  Large cell carcinoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 50-100% OR&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 3.0 mg/dL&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT no greater than 3 times ULN&#xD;
&#xD;
          -  PT no greater than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 3.0 mg/dL&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe chronic obstructive pulmonary disease that would preclude study&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No contraindications to bronchoscopy&#xD;
&#xD;
          -  No porphyria&#xD;
&#xD;
          -  No hypersensitivity to porphyrin or porphyrin-like compounds&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior biologic therapy for lung cancer allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior endocrine therapy for lung cancer allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent external beam radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No concurrent surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Prior therapy for lung cancer allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory M. Loewen, DO, FCCP</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>June 24, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2003</study_first_posted>
  <last_update_submitted>March 3, 2011</last_update_submitted>
  <last_update_submitted_qc>March 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Gregory Loewen, MD</name_title>
    <organization>Roswell Park Cancer Institute</organization>
  </responsible_party>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

